Nitec's Lodotra cleared for EU approvals
This article was originally published in Scrip
Executive Summary
Nitec Pharma's circadian rheumatoid arthritis product, Lodotra (prednisone), developed usingSykePharma's Geoclock technology, has been recommended for approval in Germany; it will be marketed there byMerck KGaA, with launch expected in the first half of this year.